Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jiaheng Guan"'
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTBackground Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, exhibiting a more unfavorable prognosis than multiple myeloma. PCL is classified into pPCL and sPCL. Recently, the IMWG has recommended new PCL definition cr
Externí odkaz:
https://doaj.org/article/3077fd66aca941de9254fdfbfcfdebb7
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTMyelodysplastic syndromes (MDS) refer to a set of clonal hematopoietic disorders with fusion transcript as disease progression. Breakpoint cluster region/abelson (BCR::ABL) fusion mostly occurs during the progressive phase from MDS to higher
Externí odkaz:
https://doaj.org/article/380c001401df4db782bb01a6cea55458
Publikováno v:
Molecular Cytogenetics, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract Background Novel fusion genes such as ZNF384, have been identified in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in recent years. Patients harboring ZNF384 rearrangements have a distinctive immunophenotype with weak CD10 and abe
Externí odkaz:
https://doaj.org/article/9d1cb12a1f2b4b8ca2bb1b1c511b1d59
Publikováno v:
Biomolecules, Vol 13, Iss 2, p 250 (2023)
Hematologic malignancies (HMs) mainly include acute and chronic leukemia, lymphoma, myeloma and other heterogeneous tumors that seriously threaten human life and health. The common effective treatments are radiotherapy, chemotherapy and hematopoietic
Externí odkaz:
https://doaj.org/article/f211cedf03ea4e4c87a354ef47a076b0
Publikováno v:
Medicine. 101(50)
Immunotherapy with programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors has been widely used in the treatment of solid tumors and Hodgkin lymphoma, demonstrating powerful efficacy and good safety. However, there is
Publikováno v:
International Journal of Biological Sciences
Breast cancer is the most commonly diagnosed and the most lethal cancer in females both in China and worldwide. Currently, the origin of cancer stem cells, the heterogeneity of cancer cells, the mechanism of cancer metastasis and drug resistance are
Background: Novel fusion genes such as ZNF384 have been identified in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in recent years. Patients harboring ZNF384 rearrangement have a distinctive immunophenotype with weak CD10 and aberrant CD13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8de56d778fb43237bea8ff5165dd5023
https://doi.org/10.21203/rs.3.rs-944737/v1
https://doi.org/10.21203/rs.3.rs-944737/v1
Publikováno v:
Molecular cytogenetics. 15(1)
Background Novel fusion genes such as ZNF384, have been identified in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in recent years. Patients harboring ZNF384 rearrangements have a distinctive immunophenotype with weak CD10 and aberrant CD1
Publikováno v:
International Journal of Biological Sciences; 2021, Vol. 17 Issue 8, p2069-2079, 11p